Table 4.
Discriminative performance of MMR prediction strategies, stratified by ascertainment
| Strategy | Total cohort (N=1651), c-statistic |
Population-based (N=1181), c-statistic |
Clinic-based (N=470), c-statistic |
|---|---|---|---|
| PREMM1,2,6 | 0.90 (0.88 to 0.92) | 0.84 (0.81 to 0.88) | 0.88 (0.84 to 0.93) |
| MSI | 0.77 (0.74 to 0.79) | 0.82 (0.78 to 0.86) | 0.79 (0.76 to 0.82) |
| IHC | 0.82 (0.80 to 0.84) | 0.88 (0.85 to 0.90) | 0.79 (0.76 to 0.82) |
| MSI + IHC | 0.82 (0.80 to 0.84) | 0.90 (0.87 to 0.92) | 0.80 (0.78 to 0.83) |
| PREMM1,2,6 + MSI | 0.93 (0.92 to 0.95) | 0.92 (0.89 to 0.94) | 0.93 (0.89 to 0.96) |
| PREMM1,2,6 + IHC | 0.94 (0.92 to 0.96) | 0.94 (0.92 to 0.96) | 0.92 (0.88 to 0.96) |
| PREMM1,2,6 + MSI + IHC | 0.94 (0.93 to 0.96) | 0.94 (0.92 to 0.97) | 0.94 (0.89 to 0.96) |
IHC, immunohistochemistry; MSI, microsatellite instability.